Skip to main content

NHS England Explore Manufacturing Medical Cannabis Product - The Cannabis Exchange

NHS England Explore Manufacturing Medical Cannabis Product - The Cannabis Exchange

The NHS is exploring the possibility of manufacturing medical cannabis products for clinical trials of children who suffer from severe epilepsy. Compounds known as cannabinoids which are found in the cannabis plant have been found to have some anti-seizure potential in certain forms of the condition. 

Medical cannabis was legalised in the UK in November 2018 following campaigns from the families of children with treatment-resistant epilepsy. Parents of Billy Caldwell and Alfie Dingley claimed that their children had experienced significant improvements after being treated from cannabis oils sourced from other countries including Canada and the Netherlands.

However, since cannabis was rescheduled in 2018 no prescriptions have been provided through the NHS for the approved cannabis product. This is largely down to healthcare workers being unfamiliar and unconfident with the potential of cannabinoids.

Many patients have relied on private clinics for access to cannabis medications. Although access and cost of such medications is improving, families can often face large expenses for medical cannabis products. However, the NHS has now announced plans to manufacture cannabis oils in preparation for clinical trials.

In a letter to a number of MPs, revealed by The Telegraph, Professor Stephen Powis, the medical director of NHS England, said:

“Progress has been made on the design and approval of a randomised clinical trial in refractory epilepsy, where the effectiveness of cannabis-based medicinal products can be assessed.”

It is hoped that the findings from the clinical trials, earmarked to begin early next year, will provide much needed evidence for the broader use of medical cannabis in the NHS. Some past studies have found that a combination of cannabis compunds CBD and THC can help to significantly reduce seizures in treatment-resistant epilepsy.

In November 2019, the National Institute for Health and Care Excellence (NICE) published its recommendations for the use of medical cannabis. Currently, GW Pharmaceuticals’ Epidyolex is the only medical cannabis product currently recommended for the treatment of epilepsy in the UK. However, use of the product is only recommended in cases of two forms of the condition – Lennox-Gastaut and Dravet syndrome.

Cannabis was moved to schedule 2 of the Controlled Substances Act in November 2018, allowing for the medical use and research of the plant and its derivatives. More recently, Epidolyex was moved to schedule 5, making it the first cannabis-based medication placed in this category.

No Newer Articles

Let's block ads! (Why?)



https://canex.co.uk/nhs-england-explore-...s-product/

from potads - All Forums learn more

Popular posts from this blog

Martha Stewart launches CBD line in crowded market - CNN

Martha Stewart launches CBD line in crowded market - CNN The hemp-derived, cannabidiol-rich gummies, soft gels and oil drops officially launched on Thursday after more than a year in development. The products are the result of the style maven's partnership with Canopy Growth ( CGC ) , the Canadian cannabis company with a multibillion-dollar backer in US alcohol giant Constellation Brands ( STZ ) . Stewart joined Canopy as an adviser in early 2019 for the express purpose of developing cannabis products for humans and their pets after being introduced to Canopy's founder by her friend Calvin Broadus Jr. -- the rapper and businessman better known as Snoop Dogg. His Leafs by Snoop cannabis brand is produced by Canopy. The initial Martha Stewart CBD products, which range from $34.99 to $44.99, will be sold online at Canopy's e-commerce site . The pet products are expected to debut later this year. "I was surprised to learn that while most people have heard of ...
Read more

The Half-Legal Cannabis Trap - POLITICO

The Half-Legal Cannabis Trap - POLITICO LOS ANGELES — Everything about Kelvin’s job in a neighborhood southwest of downtown seemed like any other assignment, if not a little more exciting. The 40-year-old, who had previously worked as an electrician, had been employed since 2015 by a private security company that contracted him out to guard marijuana dispensaries. In 2019, he was protecting one of the thousand or so cannabis stores in California’s biggest city—part of an industry that has grown less and less underground since 1996, when the state first legalized medical marijuana. Kelvin, who asked not to be identified beyond his middle name to avoid professional retaliation, doesn’t smoke pot, but says the gig felt like the future. He grew up in a time when other Black people he knew in Los Angeles would go to jail for possessing even small amounts of the drug. Now, customers could walk into shops like the one he was guarding, many of which can be identified by green crosses on...
Read more

Cannabis news worldwide -- Some Indian farmers are turning moon-gazers

Some Indian farmers are turning moon-gazers A growing number of cultivators opt for biodynamic techniques to give farming a zodiac twist Sarvdaman Patel , 69, stands between rows of legumes and parsley at high noon, but it is not the harsh sun that bothers him. He is obsessed with the moon. "It is currently in the Air sign which is ideal for flowering plants," he remarks, peering at the marigolds. Patel is no Bejan Daruwala. He is an Indian farmer who has been using biodynamic (BD) techniques for the last 16 years on his farm in Gujarat's Anand. The BD cultivation calendar is based on the moon's movement through each zodiac every two-and-a-half days covering all 12 signs every month. An unofficial estimate by the Biodynamic Association of India (BDAI) says about one lakh farmers in Maharashtra, Andhra Pradesh, Punjab and Uttarakhand practise biodynamic farming. However, most of the produce is sold under the generic 'organic' label as few consumers unde...
Read more